$CNBX
CNBX Pharmaceuticals Inc. Stock $cnbx

$cnbx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000168316824008433 Filed on November 29, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024
Revenue	$0.00		$130.1K
YoY Change	-100.0%		-68.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$518.4K
YoY Change			-43.11%
% of Gross Profit
Research & Development	$0.00		$194.8K
YoY Change	-100.0%		-54.86%
% of Gross Profit
Depreciation & Amortization	$0.00		$72.32K
YoY Change	-100.0%		-55.37%
% of Gross Profit
Operating Expenses	$36.84K		$713.2K
YoY Change	-85.9%		-46.84%
Operating Profit	-$36.84K		-$583.1K
YoY Change	-78.57%		-37.39%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$2.485K		$23.12K
YoY Change	-137.52%		-56.06%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$34.35K		-$695.2K
YoY Change	-80.76%		-81.26%
Net Earnings / Revenue			-534.46%
Basic Earnings Per Share	$0.00		-$0.02
Diluted Earnings Per Share	$0.00		-$0.02
COMMON SHARES
Basic Shares Outstanding	31.11M shares	31.11M shares	30.25M shares
Diluted Shares Outstanding	31.11M shares		30.25M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$17.34K	$26.42K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$22.31K	$31.38K
YoY Change	-85.22%	-86.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$22.31K	$31.38K
Total Long-Term Assets	$0.00	$0.00
Total Assets	$22.31K	$31.38K
YoY Change	-94.24%	-93.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.537M	$2.511M
YoY Change	2.19%	-0.2%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.537M	$2.511M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$24.99M	-$24.95M
YoY Change	2.25%	2.87%
Common Stock	$3.111K	$3.111K
YoY Change	9.89%	37.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.514M	-$2.480M
YoY Change
Total Liabilities & Shareholders Equity	$22.31K	$31.38K
YoY Change	-94.24%	-93.71%

Cashflow Statement

Concept	2024 Q4	2024
OPERATING ACTIVITIES
Net Income	-$34.35K	-$695.2K
YoY Change	-80.76%	-81.26%
Depreciation, Depletion And Amortization	$0.00	$72.32K
YoY Change	-100.0%	-55.37%
Cash From Operating Activities	-$39.08K	-$244.3K
YoY Change	-45.61%	117.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$113.5K
YoY Change	-100.0%	359.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$30.00K	$27.51K
YoY Change	20.03%	-72.49%
NET CHANGE
Cash From Operating Activities	-$39.08K	-$244.3K
Cash From Investing Activities	$0.00	$113.5K
Cash From Financing Activities	$30.00K	$27.51K
Net Change In Cash	-$9.077K	-$103.3K
YoY Change	-81.11%	-947.88%
FREE CASH FLOW
Cash From Operating Activities	-$39.08K	-$244.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-583139	usd
CY2023	CNBX	Capital Loss CapitalLoss	2726231	usd
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001343009
CY2023	CNBX	Expiration Of Warrants ExpirationOfWarrants		usd
CY2023	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings		usd
CY2024	CNBX	Loss Gain From Convertible Loan Valuation LossGainFromConvertibleLoanValuation		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-08-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2024	dei	Security12b Title Security12bTitle	Common Stock, $.0001 Par Value
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	437714	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31111352	shares
CY2023	dei	Auditor Firm AuditorFirmId	6629
CY2024	dei	Auditor Firm AuditorFirmId	6816
CY2023	dei	Auditor Name AuditorName	Weinstein International. C.P.A
CY2023	dei	Auditor Location AuditorLocation	Tel - Aviv, Israel
CY2024	dei	Auditor Name AuditorName	Elkana Amitai. C.P.A.
CY2024	dei	Auditor Location AuditorLocation	Mitzpe Netofa, Israel
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26416	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129696	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4967	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	94612	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	31383	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	224308	usd
CY2024Q3	us-gaap	Investments Investments	0	usd
CY2023Q3	us-gaap	Investments Investments	0	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	274731	usd
CY2024Q3	us-gaap	Assets Assets	31383	usd
CY2023Q3	us-gaap	Assets Assets	499039	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	40841	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	335915	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1295107	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1343584	usd
CY2024Q3	CNBX	Due To Related Party DueToRelatedParty	1175415	usd
CY2023Q3	CNBX	Due To Related Party DueToRelatedParty	836829	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2511363	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2516328	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31111352	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31111352	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22611352	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22611352	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	3111	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2261	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22471309	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22239652	usd
CY2024Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	0	usd
CY2023Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	0	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24954400	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24259202	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-2479980	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2017289	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31383	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	499039	usd
CY2024	us-gaap	Revenues Revenues	130074	usd
CY2023	us-gaap	Revenues Revenues	410165	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	194788	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	431565	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	518426	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	909980	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	713214	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1341545	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-931380	usd
CY2024	CNBX	Capital Loss CapitalLoss	88934	usd
CY2024	CNBX	Financial Loss Net FinancialLossNet	23124	usd
CY2023	CNBX	Financial Loss Net FinancialLossNet	52623	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-695198	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3710234	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-695198	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3710234	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30247691	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30247691	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8824636	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8824636	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-695198	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3710234	usd
CY2024	us-gaap	Depreciation Depreciation	72320	usd
CY2023	us-gaap	Depreciation Depreciation	162061	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	139720	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	180480	usd
CY2024	CNBX	Interest On Convertible Loan InterestOnConvertibleLoan	16798	usd
CY2023	CNBX	Interest On Convertible Loan InterestOnConvertibleLoan	54811	usd
CY2024	CNBX	Capital Loss Gain CapitalLossGain	-88934	usd
CY2023	CNBX	Capital Loss Gain CapitalLossGain	-2726232	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-89644	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	13840	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43513	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	487969	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-244269	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-112521	usd
CY2024	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	114673	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2024	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	0	usd
CY2023	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	24702	usd
CY2024	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1196	usd
CY2023	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	-0	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	113477	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24702	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	27512	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27512	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-103280	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12181	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129696	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117515	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26416	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129696	usd
CY2024	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	92787	usd
CY2023	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	569930	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1632311	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	180480	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	569930	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2574846	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3710234	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2017289	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	139720	usd
CY2024	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	92787	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-695198	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-2479980	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-695198	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24954400	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zCtNa3ZnldS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zmRdmvYl7ZL4">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, impairment valuation of intangible assets, valuation of share-based payments and the valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zGiMcS4KeGBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_z4Vl1SaOgVp9">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents with high credit quality financial institutions. There is Federal Deposit Insurance on the Company’s U.S. bank accounts for up to $<span id="xdx_90B_eus-gaap--CashFDICInsuredAmount_iI_c20240831_zPxUi7jBlbe8" title="Federal deposit insurance">250,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024	CNBX	Revenue Recognition Sales Of Goods And Licensing Fees RevenueRecognitionSalesOfGoodsAndLicensingFees	<p id="xdx_848_ecustom--RevenueRecognitionSalesOfGoodsAndLicensingFees_zEdvNT5i9X36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from service agreements is recognized over the periods from which the Company performing the service and is entitled to the respective payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:120
CY2024	CNBX	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.210	pure
CY2023	CNBX	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.210	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.210	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3466614	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3337764	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3466614	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3337764	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	128850	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	603893	usd
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24954400	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	114674	usd
CY2024	CNBX	Capital Loss CapitalLoss	88934	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	24200	usd
CY2023	CNBX	Capital Loss CapitalLoss	2726231	usd
CY2024	us-gaap	Labor And Related Expense LaborAndRelatedExpense	348109	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	461375	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	139720	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	180480	usd
CY2024	CNBX	Legal And Professional Fees LegalAndProfessionalFees	-55385	usd
CY2023	CNBX	Legal And Professional Fees LegalAndProfessionalFees	149108	usd
CY2024	us-gaap	General Insurance Expense GeneralInsuranceExpense	32410	usd
CY2023	us-gaap	General Insurance Expense GeneralInsuranceExpense	68278	usd
CY2024	us-gaap	Marketing Expense MarketingExpense	0	usd
CY2023	us-gaap	Marketing Expense MarketingExpense	1223	usd
CY2024	us-gaap	Other General Expense OtherGeneralExpense	53572	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	49516	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	518426	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	909980	usd
CY2024	us-gaap	Interest Paid InterestPaid	293	usd
CY2023	us-gaap	Interest Paid InterestPaid	1174	usd
CY2024	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	19318	usd
CY2023	CNBX	Loss Gain From Convertible Loan Valuation LossGainFromConvertibleLoanValuation	54810	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3513	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3361	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23124	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52623	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-008433-index-headers.html	Edgar Link	pending
0001683168-24-008433-index.html	Edgar Link	pending
0001683168-24-008433.txt	Edgar Link	pending
0001683168-24-008433-xbrl.zip	Edgar Link	pending
cnbx-20240831.xsd	Edgar Link	pending
cnbx_ex3101.htm	Edgar Link	pending
cnbx_ex3102.htm	Edgar Link	pending
cnbx_ex3201.htm	Edgar Link	pending
cnbx_ex3202.htm	Edgar Link	pending
cnbx_i10k-83124.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
cnbx-20240831_def.xml	Edgar Link	unprocessable
cnbx-20240831_lab.xml	Edgar Link	unprocessable
cnbx-20240831_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cnbx_i10k-83124_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cnbx-20240831_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNBX
CNBX Pharmaceuticals Inc. Stock $cnbx

2024 Q4 Form 10-K Financial Statement

#000168316824008433 Filed on November 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX CNBX Pharmaceuticals Inc. Stock $cnbx

2024 Q4 Form 10-K Financial Statement

#000168316824008433 Filed on November 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX
CNBX Pharmaceuticals Inc. Stock $cnbx